Biota Holdings
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform. Its mission is to transform global health by pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases, making vaccines more accessible, effective, and easier to distribute. The company focuses on innovative vaccine science, including vaccines for COVID-19, norovirus, influenza, and HPV, utilizing a unique modular platform called VAAST that combines recombinant adenovirus vectors, viral antigens, and molecular adjuvants. Vaxart aims to deliver vaccines directly to the small intestine to stimulate comprehensive immune responses, including mucosal immunity, which could offer broader and longer-lasting protection. Its vaccines are designed to be thermostable, easy to administer, and capable of rapid development, with a focus on global accessibility and addressing unmet medical needs.
Industries
Nr. of Employees
medium (51-250)
Biota Holdings
Notting Hill, Victoria, Australia, Oceania
Products
Oral recombinant tablet vaccine — COVID-19 program
An orally delivered recombinant tablet vaccine candidate designed to elicit mucosal (intestinal IgA) and systemic immune responses against SARS‑CoV‑2; being evaluated in randomized, comparator-controlled clinical trials including a large Phase 2b study.
Oral recombinant tablet vaccine — Norovirus program
A bivalent oral tablet vaccine candidate targeting the genogroups most associated with norovirus infections, developed to induce intestinal mucosal antibodies and systemic responses; includes maternal immunization studies assessing antibody transfer to breast milk and Phase 1/Phase 2 challenge evaluations.
Oral recombinant tablet vaccine — Influenza program
Oral tablet vaccine program targeting seasonal influenza strains, including work on monovalent to multivalent formulations and human challenge studies demonstrating reductions in infection and shedding compared with an injectable comparator.
Therapeutic oral recombinant vaccine — HPV immuno-oncology program
An oral recombinant vaccine program developed as a therapeutic approach for HPV-associated disease, with preclinical evidence of T-cell induction, tumor reduction, and survival benefit in animal models.
Oral recombinant tablet vaccine — COVID-19 program
An orally delivered recombinant tablet vaccine candidate designed to elicit mucosal (intestinal IgA) and systemic immune responses against SARS‑CoV‑2; being evaluated in randomized, comparator-controlled clinical trials including a large Phase 2b study.
Oral recombinant tablet vaccine — Norovirus program
A bivalent oral tablet vaccine candidate targeting the genogroups most associated with norovirus infections, developed to induce intestinal mucosal antibodies and systemic responses; includes maternal immunization studies assessing antibody transfer to breast milk and Phase 1/Phase 2 challenge evaluations.
Oral recombinant tablet vaccine — Influenza program
Oral tablet vaccine program targeting seasonal influenza strains, including work on monovalent to multivalent formulations and human challenge studies demonstrating reductions in infection and shedding compared with an injectable comparator.
Therapeutic oral recombinant vaccine — HPV immuno-oncology program
An oral recombinant vaccine program developed as a therapeutic approach for HPV-associated disease, with preclinical evidence of T-cell induction, tumor reduction, and survival benefit in animal models.
Expertise Areas
- Oral vaccine platform development
- Mucosal immunology and mucosal vaccine design
- Viral vaccine research and development
- Preclinical efficacy and challenge model design
Key Technologies
- Non-replicating adenoviral vector platforms
- Double-stranded RNA molecular adjuvants (TLR3 agonists)
- Oral tablet/capsule gastrointestinal-targeted delivery
- Radio-controlled capsule site-specific delivery